Results 121 to 130 of about 52,166 (258)

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source

Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet, Iain K. Robertson, Sharon P. Luccisano, Michelle L. Kilpatrick   +3 more
wiley   +1 more source

Improving obesity management: Insights from the ACTION Switzerland survey of people with obesity, physicians and dietitians

Clinical Obesity, Volume 15, Issue 2, April 2025.
PwO, people with obesity. Summary ACTION Switzerland (NCT05232786) examined obesity‐related perceptions, attitudes, behaviours and potential barriers to treatment among people with obesity (PwO) and healthcare professionals (HCPs). In March/April 2022, adult PwO (body mass index ≥30 kg/m2, per self‐reported height/weight) and physicians/certified ...
Dominique Durrer, Patrick Pasi, Ralph Peterli, Doris Fischer‐Taeschler, Gabriela Fontana, Gionata Cavadini, Philipp A. Gerber   +6 more
wiley   +1 more source

Changes in gastrointestinal motility and gut hormone secretion after Roux‐en‐Y gastric bypass and sleeve gastrectomy for individuals with severe obesity

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Background Bariatric surgery is very effective in long‐term weight management. The present study was undertaken to investigate the short‐term effects of sleeve gastrectomy (SG) and of Roux‐en‐Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro‐cecal transit time and (b) secretion of regulatory gut ...
Jennifer A. Wilbrink, Mark van Avesaat, Simon W. Nienhuijs, Arnold Stronkhorst, Ad A. M. Masclee   +4 more
wiley   +1 more source

Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity

Periodontology 2000, EarlyView., 2023
Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti, Jean E. Suvan, Francesco D'Aiuto   +2 more
wiley   +1 more source

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton, Elham Kamran, Lehana Thabane, Peter Yin, Rebecca Christensen   +4 more
wiley   +1 more source

Prurigo Pigmentosa – an increasingly diagnosed dermatological condition associated with ketogenic diet

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
SUMMARY Prurigo pigmentosa (PP) is a rare inflammatory dermatosis, clinically characterized by intensely pruritic, erythematous papules and papulovesicles, with reticular hyperpigmentation upon healing. We herein report four cases in adults of different ethnic backgrounds, in which the disease was associated with ketogenic metabolic states due to ...
Antigona Aliu, Milan Vidakovic, Marcel Krauß, Julia Hyun, Frank Oellig, Thilo Gambichler, Valentina Laura Müller, Alexander Kreuter   +7 more
wiley   +1 more source

Impact of Bariatric Surgery on Newborn Growth Parameters. [PDF]

Int J Pediatr
Aoun R, Hallit S, Nicolas G.
europepmc   +1 more source

Access to bariatric surgery in Aotearoa, New Zealand - a scoping review. [PDF]

Int J Equity Health
Appleby N, Tuivaiti E, Kahi M, Harwood M, Beban G, Kulasegaran S, Cavadino A, Selak V, Rahiri JL.   +8 more
europepmc   +1 more source